KRAS and urinary bladder carcinoma: As an oncogene, KRAS mutations were reported frequently in a variety of tumors, including colorectal cancer (Prior et al., 2012), pancreatic cancer (Arner et al., 2019), and bladder cancer (Santha et al., 2020).